Productive interim statistics from continual V5 Work in IIb imm01 test against tuberculosis
Posted in Disease, Infection on January 24th, 2011Unaffected Network Ltd., a group in the duty of growth and commercialization of unsusceptible therapies, announced today that its newly acquired enterprise, Immunitor Inc., has published interim details from the evolving Aspect IIb imm01 clinical misfortune of V5 in tuberculosis (including multidrug obstinate TB, MDR-TB) conducted at its wink placement in Ukraine. The results from the Bureau of Phtysiatry and Pulmonology of Kharkov Medical University Read the rest of this entry »
